Terns Pharmaceuticals Inc’s recent filing unveils that its Chief Medical Officer Kuriakose Emil unloaded Company’s shares for reported $7407.0 on Oct 01 ’25. In the deal valued at $7.85 per share,944 shares were sold. As a result of this transaction, Kuriakose Emil now holds 51,520 shares worth roughly $0.44 million.
Then, Kuriakose Emil sold 853 shares, generating $3,640 in total proceeds. Upon selling the shares at $4.27, the Chief Medical Officer now owns 52,464 shares.
Before that, Gengos Andrew bought 10,000 shares. Terns Pharmaceuticals Inc shares valued at $39,283 were divested by the Chief Financial Officer at a price of $3.93 per share. As a result of the transaction, Gengos Andrew now holds 25,000 shares, worth roughly $0.21 million.
Truist initiated its Terns Pharmaceuticals Inc [TERN] rating to a Buy in a research note published on October 15, 2025; the price target was $20. A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in mid September with a ‘”an Overweight”‘ rating. William Blair started covering the stock on February 28, 2025. It rated TERN as “a Mkt perform”.
Price Performance Review of TERN
On Tuesday, Terns Pharmaceuticals Inc [NASDAQ:TERN] saw its stock jump 6.58% to $8.59. Over the last five days, the stock has gained 5.79%. Terns Pharmaceuticals Inc shares have risen nearly 27.26% since the year began. Nevertheless, the stocks have risen 55.05% over the past one year. While a 52-week high of $9.03 was reached on 10/16/25, a 52-week low of $1.87 was recorded on 04/07/25.
Levels Of Support And Resistance For TERN Stock
The 24-hour chart illustrates a support level at 7.95, which if violated will result in even more drops to 7.32. On the upside, there is a resistance level at 9.05. A further resistance level may holdings at 9.51.
How much short interest is there in Terns Pharmaceuticals Inc?
A steep rise in short interest was recorded in Terns Pharmaceuticals Inc stocks on 2025-10-15, growing by 2.05 million shares to a total of 10.36 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 8.31 million shares. There was a rise of 19.82%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 31, 2024 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $82 price target.
